12:00 AM
Oct 25, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Alemtuzumab: Additional Phase II data

Follow-up data from 195 patients in the open-label, U.S. and European Phase II CAMMS223 trial showed that a significantly greater proportion of patients treated with alemtuzumab were SAD-free at 5 years vs. Rebif interferon beta-1a (87% vs. 62%, p<0.0001). The annualized relapse rate (ARR) for alemtuzumab was 0.11 compared to 0.35 for Rebif at 5 years. Additionally, alemtuzumab improved mean Expanded Disability Status Scale (EDSS) scores from baseline to 5 years by 0.3 points vs. a 0.46 point...

Read the full 389 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >